Eybna Technologies Overview
Eybna is a technology company and terpene manufacturer. Eybna's R&D center aims to contribute to the health of mankind by utilizing the therapeutic benefits of cannabis phytochemicals, with a focus on terpenes. Eybna's partnerships with academia and industry partners allow the company to constantly integrate advanced research into product development, transforming valuable scientific knowledge into easily applicable products, for the immediate benefit of people worldwide. Eybna has an R&D center based in Israel and a US office based in California.
Latest News
growth-positive
New Research Into Terpenes Could Change Medicine Forever
The article discusses the pioneering work of Eybna Technologies in the field of cannabis science. Eybna has made significant discoveries in the study of terpenes, cannabinoids, and their interactions with the endocannabinoid system. In 2020, Eybna discovered a cannabinoid formulation that effectively blocked the novel coronavirus from penetrating living cells. They are now conducting clinical studies on the formulation as a potential treatment for COVID-19. Eybna has also developed receptor-specific cannabinoid formulations, which are unique in the industry. These formulations target specific wellness goals and are composed of ingredients that are effective for producing certain effects, such as pain relief or sleep. Eybna plans to introduce these formulations globally and partner with other companies in the cannabis and CBD industry. The article emphasizes the potential of the cannabis industry to bring about change and innovation in the pharmaceutical industry and improve the quality of life on a global scale.
InvestmentExpand
growth-positive
Eybna, an International Technology Company, Establishes Cooperation with Gat Foods (IBBL), part of CBC group - the Largest Beverage Company in Israel - to Develop a New Category of Functional Beverages
Eybna has been selected as an R&D partner by Gat Foods (IBBL) to create functional beverages using terpene formulations. The partnership marks a major milestone in the international functional beverage industry. The Global Functional Beverage Market is projected to be worth USD 198 billion by 2026. Eybnas new Receptor Specific™ Line, which offers botanical formulations for various wellness needs, was launched in October 2021. The R&D partnership between Eybna and Gat Foods (IBBL) will begin with a commercial pilot in Israel and expand to other countries. Eybna is a technology company specializing in botanical medicine, while Gat Foods (IBBL) is one of the largest beverage manufacturers and distributors in Israel.
Partners
growth-positive
International Technology Company Eybna Empowers the Next Generation of Wellness Products with Receptor-Specific™ Formulations
Eybna, a technology company specializing in cannabis and botanical medicine, has launched its Functional Line. The line includes data-driven phytochemical formulations designed to meet wellness needs such as focus, sleep, anxiety, pain, inflammation, and mood management. The formulations are the result of nearly a decade of scientific research and biological data analysis. The launch includes 10 Receptor-Specific terpene and cannabinoid proprietary formulations. Eybnas CEO and Co-founder, Nadav Eyal, stated that the new line of formulations is an important milestone in Eybnas efforts towards predictable cannabis consumption.
Expand
Successful initial results using cannabis terpenes to treat COVID-19
growth-positive
Can the smell of cannabis cure us of illness?
Israeli company Eybna specializes in terpene formulations for the cannabis industry. Terpenes are organic compounds that give scents, tastes, and health benefits to fruits, flowers, and plants, including cannabis. Eybnas proprietary terpene-based formulations are used by manufacturers in the cannabis space to enhance their products. The companys research focuses on the therapeutic properties of terpenes and other cannabis phytochemicals. Eybna offers customized terpene formulations for specific sensations or medical needs. They are also collaborating with CannaSoul Analytics to investigate terpenes as an antiviral treatment for COVID-19. Eybnas growth is positive, as more companies are interested in incorporating terpenes into their products.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Mature |
| Rounds | 0 |
| Investors | 0 |
Team Members
3
Employees: 51-200
Web & Social Links
| Website | eybna.com |
| Careers | Careers page |
Locations
Ha-Yozma St 1, Kefar Sava, 4442529, Israel
7647 Hayvenhurst Ave, Van Nuys, CA 91406, USA
Photos & Videos
2 item(s)
Eybna Technologies Business
Business models
B2B2C, B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentMedical CannabisTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyCore Technology
BiologicalsHerbalsTags (7)
natural-active-ingredientsfood-ingredientscannabispharmaceuticalsherbal-medicinepharma-companiesfood-and-beverageGeographic Markets
United StatesIsraelEybna Technologies Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Mature
Funding stage
0
Total rounds
0
Investors
Eybna Technologies Lifecycle
Eybna Technologies News
7 articles
growth-positive
New Research Into Terpenes Could Change Medicine Forever
The article discusses the pioneering work of Eybna Technologies in the field of cannabis science. Eybna has made significant discoveries in the study of terpenes, cannabinoids, and their interactions with the endocannabinoid system. In 2020, Eybna discovered a cannabinoid formulation that effectively blocked the novel coronavirus from penetrating living cells. They are now conducting clinical studies on the formulation as a potential treatment for COVID-19. Eybna has also developed receptor-specific cannabinoid formulations, which are unique in the industry. These formulations target specific wellness goals and are composed of ingredients that are effective for producing certain effects, such as pain relief or sleep. Eybna plans to introduce these formulations globally and partner with other companies in the cannabis and CBD industry. The article emphasizes the potential of the cannabis industry to bring about change and innovation in the pharmaceutical industry and improve the quality of life on a global scale.
InvestmentExpand
growth-positive
Eybna, an International Technology Company, Establishes Cooperation with Gat Foods (IBBL), part of CBC group - the Largest Beverage Company in Israel - to Develop a New Category of Functional Beverages
Eybna has been selected as an R&D partner by Gat Foods (IBBL) to create functional beverages using terpene formulations. The partnership marks a major milestone in the international functional beverage industry. The Global Functional Beverage Market is projected to be worth USD 198 billion by 2026. Eybnas new Receptor Specific™ Line, which offers botanical formulations for various wellness needs, was launched in October 2021. The R&D partnership between Eybna and Gat Foods (IBBL) will begin with a commercial pilot in Israel and expand to other countries. Eybna is a technology company specializing in botanical medicine, while Gat Foods (IBBL) is one of the largest beverage manufacturers and distributors in Israel.
Partners
growth-positive
International Technology Company Eybna Empowers the Next Generation of Wellness Products with Receptor-Specific™ Formulations
Eybna, a technology company specializing in cannabis and botanical medicine, has launched its Functional Line. The line includes data-driven phytochemical formulations designed to meet wellness needs such as focus, sleep, anxiety, pain, inflammation, and mood management. The formulations are the result of nearly a decade of scientific research and biological data analysis. The launch includes 10 Receptor-Specific terpene and cannabinoid proprietary formulations. Eybnas CEO and Co-founder, Nadav Eyal, stated that the new line of formulations is an important milestone in Eybnas efforts towards predictable cannabis consumption.
Expand
Successful initial results using cannabis terpenes to treat COVID-19
growth-positive
Can the smell of cannabis cure us of illness?
Israeli company Eybna specializes in terpene formulations for the cannabis industry. Terpenes are organic compounds that give scents, tastes, and health benefits to fruits, flowers, and plants, including cannabis. Eybnas proprietary terpene-based formulations are used by manufacturers in the cannabis space to enhance their products. The companys research focuses on the therapeutic properties of terpenes and other cannabis phytochemicals. Eybna offers customized terpene formulations for specific sensations or medical needs. They are also collaborating with CannaSoul Analytics to investigate terpenes as an antiviral treatment for COVID-19. Eybnas growth is positive, as more companies are interested in incorporating terpenes into their products.
Customers
growth-positive
Eybna and CannaSoul, Top Cannabis R&D Firms, Join Forces to Prove a Proprietary Terpene Formulation for Treating Viral Infections via Modulation of Cytokine Storm
CannaSoul and Eybna Technologies have collaborated to develop a terpene formulation for treating COVID-19. CannaSoul, a global leader in cannabis research and development, will utilize its analytical expertise to customize Eybnas NT-VRL™ terpene formulation for optimizing its anti-inflammatory and anti-viral properties. The collaboration aims to provide effective treatment options for high-risk populations and actively ill patients. CannaSoul is also conducting studies to identify cannabis molecules that can suppress the immune response to the virus and reduce the expression of the ACE2 receptor, which allows the virus to enter human cells. Eybnas NT-VRL™ formulation, composed of specific terpenes, has proven anti-viral and anti-inflammatory properties. The formulation is intended to be used via inhalation for increased bioavailability.
PartnersCustomers
growth-positive
Terpenes: Eybna Technologies Unlock the Medicinal Wonders of Cannabis
The article discusses the importance of terpenes in cannabis products and their medicinal qualities. Eybna, a company based in Israel and Los Angeles, is at the forefront of researching terpene properties and producing advanced terpene products. The company aims to improve the medicinal benefits of cannabis through its discoveries and collaborations with scientific institutions. The article highlights the potential of terpenes in unlocking the true power of the cannabis plant and their value in the growing cannabis industry. Eybnas focus on terpenes is expected to be a game changer in the medical and cannabis industry.
Customers
Eybna Technologies Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 64 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Eybna Technologies Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | funding rounds, markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515146454 |
| Crunchbase | eybna-technologies-ltd |
| Creator | Yamila Silbert |
| Creator email | yamila.urwicz@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-10-17T00:00:00.000Z |
| Created | 2015-02-15T00:00:00.000Z |
| Claimed | Yes |